The majority had invasive ductal carcinoma (84.9%), had an HER2 IHC expression of 3+ (84.9%), were ER positive (61.6%), were PR negative (56%), had a single metastatic site (48.6%), and had extra-cranial metastases only (90.8%). This evidence concerns the gene ERBB2 and invasive ductal breast carcinoma.